Velphoro is a medicine used to control blood-phosphate levels in patients with long-term kidney disease: - in adults who are on haemodialysis or peritoneal dialysis to remove waste products from the blood; - in children aged from 2 years with severe kidney disease, including those on dialysis. Velphoro should be used with a low-phosphate diet and other treatments such as calcium and vitamin D supplements which help to control bone disease linked to kidney failure and high phosphate levels. The active substance in this medicine is sucroferric oxyhydroxide (also known as mixture of polynuclear iron(III)-oxyhydroxide, sucrose (sugar) and starches).
Therapeutic Indication
### Therapeutic indication Velphoro is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). Velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with CKD stages 4-5 (defined by a glomerular filtration rate <30 mL/min/1.73 m²) or with CKD on dialysis. Velphoro should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease.
Therapeutic Area (MeSH)
ATC Code
V03AE05
ATC Item
sucroferric oxyhydroxide
Pharmacotherapeutic Group
Drugs for treatment of hyperkalemia and hyperphosphatemia
Active Substance (Summary)
INN / Common Names
EMA Name
Velphoro
Medicine Name
Velphoro
Aliases
N/A